Literature DB >> 6177399

Enhanced cell killing through the use of cell kinetics-directed treatment schedules for two-drug combinations in vitro.

S C Barranco, J T May, W Boerwinkle, S Nichols, K M Hokanson, J Schumann, W Göhde, J Bryant, L F Guseman.   

Abstract

Kinetics-directed drug treatment schedules were tested in Chinese hamster ovary cells. Ten hr after treatment with 1,2:5,6-dianhydrogalactitol (DAG) (at a dose lethal to less than 5% of the cells), a 150% enrichment of cells into the S phase of the cell cycle was observed. This blockade in S phase was reversible and was followed at 18 hr after an exposure to DAG by a 200% increase in the fraction of cells in the G2-M phases of the cell cycle. Bleomycin, known to be most effective against G2 + M cells, had the greatest effect on cell killing when administered at that time. Rapid analysis by flow microfluorometry techniques was used to determine the DAG-induced kinetics changes, thus allowing treatment with the second drugs at the most opportune time. The DAG-induced kinetics changes were also demonstrated in a line of human adenocarcinoma of the stomach in vitro and in Ehrlich ascites tumor cells in vivo. In all cases, the enrichment of cells into S phase was reversible at the doses used and was followed by a reversible blockade in G2-M.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6177399

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine.

Authors:  F Dolbeare; H Gratzner; M G Pallavicini; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

2.  Effects of diflubenzuron on growth of malignant melanoma and skin carcinoma tumors in mice.

Authors:  V K Jenkins; R T Mayer; R R Perry
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Survival and cell cycle kinetics responses of Chinese hamster ovary cells, and clones of human adenocarcinoma of the stomach and astrocytoma to diaziquone (AZQ) in vitro.

Authors:  S C Barranco; G A Schechter; W R Boerwinkle; K A Howell; N H Rubin
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs.

Authors:  S C Barranco; C M Townsend; M A Quraishi; N L Burger; H C Nevill; K H Howell; W R Boerwinkle
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.